Literature DB >> 25394898

Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population.

Yingwen Liu1, Yanghui Bi, Jia Lin, Lei Cao, Bing He, Zhi Zhang, Yongping Cui, Xuemei Zhang.   

Abstract

Complement factor I (CFI) plays an important role in the development of non-small cell lung cancer (NSCLC). This study aims to examine the association of CFI genetic variants with the risk of developing NSCLC in Chinese population. A hospital-based case-control study was conducted in 470 patients with NSCLC and 470 controls in Chinese population. Totally, 13 tag single nucleotide polymorphisms (tag SNPs) of CFI were selected by Haploview software using the HapMap database. Genotyping was performed using iPLEX Gold Genotyping Assay and Sequenom MassARRAY. The odds ratios (ORs) and 95% confidence interval (95% CI) were calculated by logistic regression model. Our results showed that individuals with rs6822976 GG genotype had a significant decreased risk of NSCLC (OR = 0.64; 95% CI = 0.42-0.98) when compared with rs6822976 AA genotype carriers. We also found that rs7671905 TT genotype exhibited a significant decreased risk of NSCLC compared with CC genotype with OR (95% CI) of 0.55 (0.33-0.91). There was no significant association between other selected SNPs and the risk of NSCLC. When stratified by smoking status, the decreased risk of NSCLC was observed to be associated with the genotype with at least one rs6822976 G allele among non-smokers (OR = 0.66; 95% CI = 0.47-0.93), but not among smokers (OR = 1.01; 95% CI = 0.67-1.53). For CFI rs7671905 polymorphism, the individuals with at least one T allele have a decreased risk of NSCLC with OR (95 % CI) of 0.71 (0.51-0.99), but not among smokers (OR = 0.93; 95% CI = 0.61-1.41). When stratified by age, we found that rs7671905 TT genotype has contributed to the decreased risk of NSCLC among older subjects with OR (95% CI) of 0.46 (0.23-0.95), but not among younger subjects with OR (95% CI) of 0.64 (0.31-1.34) (P(interaction) = 0.03). After stratifying by sex, our study showed that rs7671905 TT genotype was related to the risk of NSCLC among males (OR = 0.53; 95% CI = 0.29-0.98), but not among females (OR = 0.62; 95% CI = 0.25-1.57) (P(interaction) = 0.03). CFI genetic variants played an important role in the development of NSCLC in Chinese population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394898     DOI: 10.1007/s13277-014-2801-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

Review 1.  Cancer and the complement cascade.

Authors:  Martin J Rutkowski; Michael E Sughrue; Ari J Kane; Steven A Mills; Andrew T Parsa
Journal:  Mol Cancer Res       Date:  2010-09-24       Impact factor: 5.852

Review 2.  The role of complement in inflammatory diseases from behind the scenes into the spotlight.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

3.  Additional evidence to support the role of a common variant near the complement factor I gene in susceptibility to age-related macular degeneration.

Authors:  Naoshi Kondo; Hiroaki Bessho; Shigeru Honda; Akira Negi
Journal:  Eur J Hum Genet       Date:  2010-01-20       Impact factor: 4.246

4.  Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk.

Authors:  Robert P Young; Raewyn J Hopkins
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

5.  Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement.

Authors:  R R Kew; B Ghebrehiwet; A Janoff
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

6.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

7.  DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk.

Authors:  M C Stern; D M Umbach; C H van Gils; R M Lunn; J A Taylor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-02       Impact factor: 4.254

Review 8.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

9.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

10.  Cancer and complement.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Nat Biotechnol       Date:  2008-12       Impact factor: 54.908

View more
  1 in total

1.  Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.

Authors:  Barry W Neun; Yechezkel Barenholz; Janos Szebeni; Marina A Dobrovolskaia
Journal:  Molecules       Date:  2018-07-12       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.